Transcription-replication conflicts underlie sensitivity to PARP inhibitors

Area of Science:

• Molecular Biology
• Cancer Therapeutics
• Genetics

Background:

• Poly(ADP-ribose) polymerase (PARP) inhibitors are crucial for treating homologous recombination (HR)-deficient cancers.
• PARP inhibitors are believed to trap PARPs on DNA, blocking replication and causing DNA double-strand breaks that necessitate HR for repair.

Purpose of the Study:

• To investigate the precise mechanism underlying the synthetic lethality of PARP inhibitors in HR-deficient cancers.
• To elucidate the role of PARP1, TIMELESS, and TIPIN in protecting the replication machinery.

Main Methods:

• Investigated the interaction of PARP1 with TIMELESS and TIPIN in early S phase.
• Analyzed the impact of inhibiting transcription elongation on PARP inhibitor sensitivity in HR-deficient cells.
• Utilized small-interfering RNA to deplete PARP1 and assess its effect on HR-deficient cells.

Main Results:

• PARP1, TIMELESS, and TIPIN collaborate to shield the replisome from transcription-replication conflicts in early S phase.
• The synthetic lethality observed with PARP inhibitors in HR-deficient cells is attributed to unrepaired DNA damage from transcription-replication conflicts.
• Inhibiting transcription elongation rendered HR-deficient cells resistant to PARP inhibitors, and PARP1 depletion showed synthetic lethality with HR deficiency.

Conclusions:

• The therapeutic effect of PARP inhibitors in HR-deficient cancers may be achieved by targeting PARP1's enzymatic activity alone.
• Understanding the role of PARP1 in DNA repair during replication stress is critical for optimizing cancer therapy.